Literature DB >> 7473078

Pharmacokinetics of bupivacaine enantiomers in sheep: influence of dosage regimen and study design.

L E Mather1, A J Rutten, J L Plummer.   

Abstract

Bupivacaine is used as a racemate. In previous studies the mean total body clearance of R(+)-bupivacaine was found to be greater than S(-)-bupivacaine by 65% after iv bolus dose of separate enantiomers and by 20% after iv infusion to steady state of racemate. The present studies were performed to determine whether different study designs using different iv dosage regimens could influence the pharmacokinetic parameters determined for either bupivacaine enantiomer. rac-Bupivacaine.HCl was administered iv to 6 adult Merino ewes by bolus, brief infusion, and prolonged infusion. Arterial blood concentrations of R(+)- and S(-)-bupivacaine were measured by enantioselective HPLC. These regimens consistently produced lower arterial blood concentrations of R(+)-bupivacaine than S(-)-bupivacaine due to R(+)-bupivacaine having a greater initial dilution volume by 16 (95% CI = 3-29)%, volume of distribution at steady state equilibrium by 32 (95% CI = 17-32)% and mean total body clearance by 28 (95% CI = 21-35)%. The slow half-life of R(+)-bupivacaine, however, was found to be 15 (95% CI = 0-31)% longer than that of S(-)-bupivacaine. The difference between enantiomers in mean total body clearance thus was similar to the previous study based upon infusion to steady state of rac-bupivacaine. Differences in pharmacokinetics attributable to the dosage regimen consisted of a greater mean total body clearance for R(+)-bupivacaine along with a smaller terminal half life with the bolus regimen and a longer half-life of S(-)-bupivacaine after prolonged infusion. Differences in pharmacokinetics between the bupivacaine enantiomers occurred consistently in both distribution and clearance but the magnitude of the effect was less than 50% in each case. Systematic differences in pharmacokinetics associated with the dosage regimen were found mainly in terminal half-life. Dosage regimen, thus, was found to influence the pharmacokinetic results found experimentally and is therefore a significant variable in its own right.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7473078     DOI: 10.1007/bf02353791

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  27 in total

1.  Pharmacology of local anaesthetic agents. Pharmacokinetics of local anaesthetic agents.

Authors:  G T Tucker; L E Mather
Journal:  Br J Anaesth       Date:  1975-02       Impact factor: 9.166

2.  Circadian phase-dependent protein and tissular binding of three local anesthetics (bupivacaine, etidocaine, and mepivacaine) in mice: a possible mechanism of their chronotoxicokinetics?

Authors:  B Bruguerolle; M Prat
Journal:  Chronobiol Int       Date:  1992-12       Impact factor: 2.877

3.  Human hepatic blood flow and its relation to systemic circulation during intravenous infusion of bupivacaine or etidocaine.

Authors:  L Wiklund
Journal:  Acta Anaesthesiol Scand       Date:  1977       Impact factor: 2.105

4.  Toxicological and local anaesthetic effects of optically active isomers of two local anaesthetic compounds.

Authors:  G Aberg
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1972

5.  Comparative pharmacokinetics of fentanyl and alfentanil.

Authors:  S Bower; C J Hull
Journal:  Br J Anaesth       Date:  1982-08       Impact factor: 9.166

6.  Cardiovascular effects and regional clearances of intravenous ropivacaine in sheep.

Authors:  A J Rutten; L E Mather; C Nancarrow; P A Sloan; C F McLean
Journal:  Anesth Analg       Date:  1990-06       Impact factor: 5.108

7.  Postoperative course of plasma protein binding of lignocaine, ropivacaine and bupivacaine in sheep.

Authors:  A J Rutten; L E Mather; J L Plummer; E C Henning
Journal:  J Pharm Pharmacol       Date:  1992-04       Impact factor: 3.765

8.  Absorption characteristics of transdermally administered fentanyl.

Authors:  J R Varvel; S L Shafer; S S Hwang; P A Coen; D R Stanski
Journal:  Anesthesiology       Date:  1989-06       Impact factor: 7.892

9.  Myocardial and cerebral drug concentrations and the mechanisms of death after fatal intravenous doses of lidocaine, bupivacaine, and ropivacaine in the sheep.

Authors:  C Nancarrow; A J Rutten; W B Runciman; L E Mather; R J Carapetis; C F McLean; S F Hipkins
Journal:  Anesth Analg       Date:  1989-09       Impact factor: 5.108

10.  Disposition of mepivacaine and bupivacaine enantiomers in sheep.

Authors:  L E Mather
Journal:  Br J Anaesth       Date:  1991-09       Impact factor: 9.166

View more
  3 in total

1.  Direct cardiac effects of intracoronary bupivacaine, levobupivacaine and ropivacaine in the sheep.

Authors:  D H Chang; L A Ladd; S Copeland; M A Iglesias; J L Plummer; L E Mather
Journal:  Br J Pharmacol       Date:  2001-02       Impact factor: 8.739

Review 2.  Analgesia for Sheep in Commercial Production: Where to Next?

Authors:  Alison Small; Andrew David Fisher; Caroline Lee; Ian Colditz
Journal:  Animals (Basel)       Date:  2021-04-14       Impact factor: 2.752

Review 3.  Recent advances in the pharmacokinetics of local anaesthetics. Long-acting amide enantiomers and continuous infusions.

Authors:  J M Thomas; S A Schug
Journal:  Clin Pharmacokinet       Date:  1999-01       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.